Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
156.4 USD | +1.93% | +4.45% | -18.27% |
Financials (USD)
Sales 2024 * | 1.87B | Sales 2025 * | 2.26B | Capitalization | 19.79B |
---|---|---|---|---|---|
Net income 2024 * | -448M | Net income 2025 * | -257M | EV / Sales 2024 * | 9.96 x |
Net cash position 2024 * | 1.13B | Net cash position 2025 * | 443M | EV / Sales 2025 * | 8.57 x |
P/E ratio 2024 * |
-44.3
x | P/E ratio 2025 * |
-84
x | Employees | 2,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.58% |
Latest transcript on Alnylam Pharmaceuticals, Inc.
1 day | +1.93% | ||
1 week | +4.45% | ||
Current month | +5.39% | ||
1 month | +3.96% | ||
3 months | +4.92% | ||
6 months | -8.48% | ||
Current year | -18.27% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 16-09-18 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 19-08-12 |
Piyush Sharma
CMP | Compliance Officer | - | 22-09-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 15-12-17 |
Charles Sigal
BRD | Director/Board Member | 72 | 22-08-21 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 19-01-09 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
5.08% | 1 M€ | +0.84% | - | |
4.04% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-11 | 156.4 | +1.93% | 717,051 |
24-06-10 | 153.5 | +0.45% | 383,075 |
24-06-07 | 152.8 | +2.33% | 862,730 |
24-06-06 | 149.3 | -1.82% | 534,229 |
24-06-05 | 152.1 | +1.54% | 785,988 |
Delayed Quote Nasdaq, June 11, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.27% | 19.79B | |
+49.21% | 56.87B | |
+39.98% | 39.72B | |
-6.86% | 39.27B | |
-4.42% | 28.73B | |
+12.00% | 26.21B | |
+29.57% | 12.28B | |
+25.41% | 12.23B | |
-0.35% | 12.12B | |
-10.99% | 10.84B |
- Stock Market
- Equities
- ALNY Stock